UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 19, 2017

 

BioLargo, Inc.

(Exact name of registrant as specified in its charter)

 

 

Delaware

 

000-19709

 

65-0159115

(State or other jurisdiction

of incorporation)

 

(Commission File Number)

 

(IRS Employer

Identification No.)

 

 

14921 Chestnut St., Westminster, California

 

92683

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code: (949) 643-9540

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

 

Emerging growth company    ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    ☐

 

 

 
 

 

   

Item 5.07      Submission of Matters to a Vote of Security Holders

 

The Company held its 2017 annual stockholder meeting on June 19, 2017. The following matters were each submitted to a vote of stockholders through the solicitation of proxies or otherwise:

 

(1) A proposal to elect the following seven individuals to our Board of Directors: Dennis P. Calvert, Kenneth R. Code, Dennis E. Marshall, Joseph L. Provenzano, Kent C. Roberts II, John S. Runyan, and Jack B. Strommen.

 

(2) Advisory approval of the Company’s executive compensation.

 

(3) A proposal to ratify the appointment of Haskell & White LLP as our independent public accounting firm for the 2017 fiscal year.

 

A quorum was present in person or by proxy. Each matter was approved. The voting results are as follows:

 

Proposal One

Votes For

Votes

Withheld

Broker

Non-Vote

 

        Dennis P. Calvert

27,539,313

295,800

28,157,420

 

        Kenneth R. Code

27,531,548

303,565

28,157,420

 

     Dennis E. Marshall

27,632,565

202,548

28,157,420

 

Joseph L. Provenzano

27,397,725

437,388

28,157,420

 

      Kent C. Roberts II

27,755,103

  80,010

28,157,420

 

          John S. Runyan

27,753,403

  81,710

28,157,420

 

       Jack B. Strommen

27,401,725

433,388

28,157,420

 
         

Proposal 2 and 3

Votes For

Votes

Against

Votes

Abstain

Broker

Non-Vote

2

31,052,733

342,142

   240,267

21,119,013

3

50,180,196

345,782

2,228,177

               -

 

 

For the Advisory Approval of Executive Compensation, prior year votes are as follows:

 

Year

 

Votes For

Votes Against

Votes Abstain

Broker

Non-Vote

2016

31,052,733

342,142

240,267

21,119,013

2015

31,788,604

  97,649

143,630

17,585,688

 

 

There were no director nominees other than as set forth above.

 

 

 
 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

                 

Date: June 21, 2017

 

 

 

BIOLARGO, INC.

         
 

 

 

 

 

 

By:

 

/s/ Dennis P. Calvert

 

 

 

 

 

 

 

 

Dennis P. Calvert

 

 

 

 

 

 

 

 

President and Chief Executive Officer

 

 

 

 

BioLargo (QB) (USOTC:BLGO)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more BioLargo (QB) Charts.
BioLargo (QB) (USOTC:BLGO)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more BioLargo (QB) Charts.